Specify a stock or a cryptocurrency in the search bar to get a summary
Resverlogix Corp.
RVXResverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company is headquartered in Calgary, Canada. Address: 4820 Richard Road SW, Calgary, AB, Canada, T3E 6L1
Analytics
WallStreet Target Price
10.75 CADP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures RVX
Dividend Analytics RVX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History RVX
Stock Valuation RVX
Financials RVX
Results | 2019 | Dynamics |